Navigation Links
Gauging efficacy of SSRI class of anti-depressants

Washington: The SSRI class of antidepressants is thought to have brought down the suicide rates in the U.S. According to a study in the journal, Public Library //of Science Medicine, nearly 30,000 lives have been saved by the use of the new SSRI antidepressants, presently used to alleviate depression.

The common anti-depressants prescribed for depression are Zoloft, Paxil and Prozac, which belong to the SSRI group.

Dr. Julio Licinio of the University of Miami, who conducted the study said,” Our findings certainly suggest that the introduction of SSRIs has contributed to reduction of suicide rates in the United States. However, the findings do not preclude the possibility of increased risk of suicide among small populations of individuals.”

He further added,” Much of the psychiatric community fears that the absence of treatment may prove more harmful to depressed individuals than the effects of the drugs themselves. Most people who commit suicide suffer from untreated depression."


'"/>




Page: 1

Related medicine news :

1. Ginsengs efficacy debatable
2. Avastin under trial to test efficacy for pancreatic tumours!
3. Tamiflu to be examined on clinical efficacy for WHO
4. Meningitis vaccine in a controversy regarding efficacy
5. Ultrasound may mean end to classic stethoscope
6. Madhya Pradesh Cops to attend Yoga classes to reduce stress and weight
7. Campaigners Say No To Cannabis Reclassification
8. World-class Facility A Must To Boost Medical Tourism In India
9. Suicide reduced by anti-depressants
Post Your Comments:
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...c Sydney Opera House was added to the list of Worl...truction of Danish architect Jorn Utzon's vision w...w cultural sites given the coveted status by UNESC...ittee, meeting in Christchurch, New Zealand. The ...
...ta, who plays the role of a woman in movie 'Hairsp...him lose weight. The star admits that having to... female character Edna Turnblad in the 2007 remake...turned-movie was the perfect combination to shed t...
...x-girlfriend Kate Middleton's curvaceous figure ha...ays been in style for her slender but athletic fig...In her recent appearances Kate appeared painfully ...y and almost flat chested. And according to specu...
...ent A.P.J. Abdul Kalam Friday called for taking ad...iagnostic tool and of tele-radiology to help the n...e was speaking during a visit to the digital radio...on of India Limited (ECIL), which is working towar...
Other Medicine News:
(Date:9/3/2008)...Updates Zingo Launch Progress and Adlea ... Conference Call Today at 11:30 am ET, SOUTH SA.../ -- Anesiva,Inc. (Nasdaq: ANSV ) announced toda...focus on commercial and late-stage product develop...harmaceutical pain management,company. The company...
(Date:9/3/2008)...epeat-Dosing Study in Subjects with ALS, RICHMOND...o,BioSciences, Inc. (Nasdaq: SGMO ) announced tod...-509-801) to evaluate its drug, SB-509, in subject...on disease for which there,are limited treatment o...n injectable formulation of a plasmid,encoding a z...
(Date:9/2/2008)...e-FirstCall/ -- Forest Laboratories, Inc.,(NYSE: ...ced results from,two global Phase III studies of a...icholinergic for the treatment of patients with ch...h the ACCLAIM/COPD I&II,(AClidinium CLinical Trial...re COPD Patients) studies, once-daily aclidinium b...
(Date:9/2/2008)...ion, ONE to Build Hope and Give Help, MINNEAPOLIS...the,Republican Party Convention are sending a mess...world including evacuees in the Gulf Coast region,...g countries: "We are here,to help.", World Vision... to do,something unconventional. This event provid...
Breaking Medicine Technology:Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6Senator Frist and Convention Delegates Support AIDS-Affected People Around the World, Raise Funds for Gustav Evacuees 2Senator Frist and Convention Delegates Support AIDS-Affected People Around the World, Raise Funds for Gustav Evacuees 3Senator Frist and Convention Delegates Support AIDS-Affected People Around the World, Raise Funds for Gustav Evacuees 4Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 378 1Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 378 2Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 378 3Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 378 4Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 378 5Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 378 6Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 378 7DOV 21 947 Demonstrates Significant Body Weight and BMI Reductions in Drug Compliant Subjects in Phase Ib Clinical Study 374 1DOV 21 947 Demonstrates Significant Body Weight and BMI Reductions in Drug Compliant Subjects in Phase Ib Clinical Study 374 2DOV 21 947 Demonstrates Significant Body Weight and BMI Reductions in Drug Compliant Subjects in Phase Ib Clinical Study 374 3DOV 21 947 Demonstrates Significant Body Weight and BMI Reductions in Drug Compliant Subjects in Phase Ib Clinical Study 374 4DOV 21 947 Demonstrates Significant Body Weight and BMI Reductions in Drug Compliant Subjects in Phase Ib Clinical Study 374 5Radiologists identify early brain marker of Alzheimers disease 1953 1Radiologists identify early brain marker of Alzheimers disease 1953 2Radiologists identify early brain marker of Alzheimers disease 1953 3Cardiac Science Applauds Mass AED Training of Pittsburgh Educators 1951 1Cardiac Science Applauds Mass AED Training of Pittsburgh Educators 1951 2Cardiac Science Applauds Mass AED Training of Pittsburgh Educators 1951 3Cardiac Science Applauds Mass AED Training of Pittsburgh Educators 1951 4
...achieved both primary and secondary endpoints of,s...ed between,valopicitabine and ribavirin ~, CAMBRID... Idenix,Pharmaceuticals, Inc. today announced resu...ple combination therapy, consisting of,valopicitab...treatment of hepatitis C, pegylated interferon and...
....--(BUSINESS WIRE)--Jun 12, 2007 - Geron,Corporati...g,GRN163L, has demonstrated good pharmacokinetics...involving patients with chronic,lymphocytic leukem...n Colowick, M.D., M.P.H., the company,s president,...in Maui, Hawaii., Favorable Pharmacokinetics; Phar...
Other Medicine Technology:Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 2Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 3Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 4Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 5Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 6Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good,Pharmacokinetics and Tolerability in Phase I/II Trial 2Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good,Pharmacokinetics and Tolerability in Phase I/II Trial 3Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good,Pharmacokinetics and Tolerability in Phase I/II Trial 4
Oscors proprietary quadripolar pacing wire design offers reliable and consistent pacing and sensing in the atrium and ventricle by combining two bipolar wires in one lead design. The wires for the at
The TME 227 T is a quadripolar pacing heartwire used for temporary cardiac pacing and monitoring during and after open-heart surgery. The TME 227 T features tines for fixation in the myocardium, whic
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially).
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially).
Medicine Products: